|
KMID : 1101420230550040298
|
|
Korean Journal of Clinical Laboratory Science
2023 Volume.55 No. 4 p.298 ~ p.305
|
|
|
Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment
|
|
Yang Chae-Eun
Kim Se-Been
Jeong Yu-Rim
Lim Jung-Yeon
|
|
|
Abstract
|
|
|
|
Burkitt’s lymphoma is a distinct subtype of non-Hodgkin’s lymphoma originating from B-cells that is notorious for its aggressive growth and association with immune system impairments, potentially resulting in rapid and fatal outcomes if not addressed promptly. Optimizing the use of Food and Drug Administration-approved medications, such as combining known safe drugs, can lead to time and cost savings. This method holds promise in accelerating the progress of novel treatments, ultimately facilitating swifter access for patients. This study explores the potential of a dual-targeted therapeutic strategy, combining the bruton tyrosine kinase-targeting drug Ibrutinib and the epidermal growth factor receptor/human epidermal growth factor receptor-2-targeting drug Lapatinib. Ramos and Daudi cell lines, well-established models of Burkitt’s lymphoma, were used to examine the impact of this combination therapy. The combination of Ibrutinib and Lapatinib inhibited cell proliferation more than using each drug individually. A combination treatment induced apoptosis and caused cell cycle arrest at the S and G2/M phases. This approach is multifaceted in its benefits. It enhances the efficiency of the drug development timeline and maximizes the utility of currently available resources, ensuring a more streamlined and resource-effective research process.
|
|
|
KEYWORD
|
|
|
Apoptosis, Ibrutinib, Lapatinib, Lymphoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|